COPD and Depression Analysis in Regard to Obstructive Pulmonary Levels

Area of Science:

• Pulmonary Medicine
• Psychiatry
• Clinical Pharmacology

Background:

• Depression is a common comorbidity in patients with Chronic Obstructive Pulmonary Disease (COPD).
• Understanding the impact of depressive symptoms on COPD severity and treatment outcomes is crucial.

Purpose of the Study:

• To evaluate the efficacy of antidepressant therapy in COPD patients with comorbid depressive disorder.
• To assess the relationship between COPD severity (FEV1 and mMRC) and depressive symptom distribution.
• To determine the impact of Selective Serotonin Reuptake Inhibitor (SSRI) therapy on depression scores in COPD patients.

Main Methods:

• Study included 87 patients diagnosed with COPD (GOLD criteria) and depressive disorder.
• Clinical and psychiatric assessments were performed using standardized instruments.
• Patients received 8 weeks of SSRI therapy, followed by statistical analysis (descriptive statistics, ANOVA).

Main Results:

• Depressive symptoms showed varied distribution across different COPD stages, correlated with FEV1 and mMRC scores (p < 0.01).
• SSRI therapy led to significant improvements in Hamilton Depression Rating Scale (HDRS) scores across all COPD severity levels (p < 0.01).

Conclusions:

• Targeted SSRI therapy is effective in managing depression in COPD patients.
• This intervention improves quality of life and overall treatment outcomes for COPD patients with depression.